1256337-24-2

Basic information

• Product Name: (2-bromo-pyridin-4-yl)-acetic acid ethyl ester
• Synonyms: (2-bromo-pyridin-4-yl)-acetic acid ethyl ester
• CAS NO: 1256337-24-2
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 1256337-24-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-bromo-pyridin-4-yl)-acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2-bromo-pyridin-4-yl)-acetic acid ethyl ester(1256337-24-2)
• EPA Substance Registry System: (2-bromo-pyridin-4-yl)-acetic acid ethyl ester(1256337-24-2)

Safety Data

• Hazardous Substances Data: 1256337-24-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2-bromo-pyridin-4-yl)-acetic acid ethyl ester is used as a building block for the synthesis of various organic compounds. Its bromine substituent allows for further functionalization and modification, making it a versatile intermediate in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2-bromo-pyridin-4-yl)-acetic acid ethyl ester is used as a precursor to biologically active compounds. Its unique structure and reactivity enable the development of new pharmaceuticals with potential therapeutic applications.
Used in Pharmaceutical Development:
(2-bromo-pyridin-4-yl)-acetic acid ethyl ester may find applications in the development of pharmaceuticals, where its chemical properties can be harnessed to create new drugs with improved efficacy and selectivity.
Used in Agrochemical Development:
Additionally, (2-bromo-pyridin-4-yl)-acetic acid ethyl ester may also be utilized in the development of agrochemicals, contributing to the creation of new pesticides or herbicides with enhanced performance and selectivity.
Used in Organic Chemistry Research:
Due to its unique structure and reactivity, (2-bromo-pyridin-4-yl)-acetic acid ethyl ester is a valuable tool for research in the field of organic chemistry. It can be employed to study various chemical reactions and mechanisms, contributing to the advancement of knowledge in this scientific discipline.

Upstream product

• 64-17-5 ethanol 
• 183483-29-6 2-(2-bromopyridin-4-yl)acetic acid 
• 1387560-71-5 diethyl 2-(2-bromopyridin-4-yl)malonate 
• 4926-28-7 2-Bromo-4-picoline 
• 105-58-8 Diethyl carbonate 

Downstream Products

• 1256337-25-3 (2-cyano-pyridin-4-yl)-acetic acid ethyl ester 
• 183483-29-6 2-(2-bromopyridin-4-yl)acetic acid 

Relevant articles and documents

SHMT INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance

While selective BRafV600E inhibitors have been proven effective clinically, acquired resistance rapidly develops through reactivation of the mitogen-activated protein kinase (MAPK) pathway. Simultaneous targeting of multiple nodes in the pathway offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Replacement pyridine group of Y-1 by a cyclopropyl formamide group afforded I-01 as a novel multitargeted kinase inhibitor template. I-01 displayed enzyme potency against Pan-Raf and receptor tyrosine kinases (RTKs). Based on the binding mode of I-01, analogues I-02-I-18 were designed and synthesized. The most promising compound I-16 potently inhibits all subtypes of Rafs with IC50 values of 3.49 (BRafV600E), 8.86 (ARaf), 5.78 (BRafWT), and 1.65 nM (CRaf), respectively. I-16 not only exhibit comparable antiproliferative activities with positive control compounds against HepG2, SW579, MV4-11, and COLO205 cell lines, but also suppress the proliferation of melanoma SK-MEL-2 harboring overexpressed BRafWT with IC50 values of 0.93 μM. The Western blot results for the ERK inhibition in human melanoma SK-MEL-2 cell lines show that I-16 inhibits the proliferation of SK-MEL-2 cell lines without paradoxical activation of ERK, which support the hypothesis that the inhibition of Pan-Raf and RTKs might be a tractable strategy to overcome the resistance of melanoma induced by the therapy with the current selective BRafV600E inhibitors.

Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

BETA-LACTAMASE INHIBITORS

Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.